What is OnKure Therapeutics, Inc.'s debt issuance proceeds?

OnKure Therapeutics, Inc. (OKUR) reported debt issuance proceeds of $1.5M in Q4 2024.

What does debt issuance proceeds mean?

Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.

BillionToOne, Inc. BLLN

$30M—

Revenue-—

Operating income-$15.6M+8.1%

Net income-$15.2M+4.8%

EPS (diluted)-$1.11+6.7%

Cash & equivalents$192.1M+98.7%

Total debt$409.0K-57.2%

Total equity$184.4M+103%

Total assets$198.7M+98.9%

Operating cash flow-$12.9M+7.6%

CapEx$5.0K-72.2%

Free cash flow-$12.9M+7.7%

Market cap$184.2M+72.6%

Enterprise value-$7.49M-127%

Return on equity-42.7%—

Debt / equity0×0.0×

Current ratio13.8×+2.6×

Reported directly by OnKure Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromConvertibleDebt.

The official record: OnKure Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is OnKure Therapeutics, Inc.'s debt issuance proceeds?: OnKure Therapeutics, Inc. (OKUR) reported debt issuance proceeds of $1.5M in Q4 2024.
What does debt issuance proceeds mean?: Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.